TMS-EEG Biomarkers for Chronic Pain

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Chronic Pain
Interventions
DEVICE

QuantalX DELPHI-MD (TMS-EEG)

Direct Electro-Physiological Imaging medical device (DELPHI-MD), developed by QuantalX Neuroscience, is a neurophysiological assessment system which utilizes a specific TMS-EEG protocol that automatically analyzes specific features of this brain response to reproduce numerical output measures. DELPHI-MD has previously shown to differentiate different healthy age groups, mild dementia and Parkinson's Disease (PD) from age matched healthy control. In addition, DELPHI-MD measures are correlated to white matter microstructural differences in post stroke and TBI patients. This multimodal approach allows for the evaluation of several neurophysiological mechanisms such as cortical reactivity, excitation and inhibition in local and distal regions, effective connectivity, and neural plasticity, characterized as modifications that outlast the stimulation period. The investigators predict that Delphi-MD has the potential to identify features of brain function altered in pain syndromes.

Trial Locations (1)

94107

RECRUITING

UCSF, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER